Etanercept
Enbrel · Biosimilar: Erelzi (etanercept-szzs)
Indications for Etanercept
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rheumatoid arthritis | Adults | Monotherapy or combination with MTX | FDA Approved |
| Polyarticular juvenile idiopathic arthritis (pJIA) | ≥2 years | Monotherapy or with NSAIDs/glucocorticoids | FDA Approved |
| Psoriatic arthritis | Adults | Monotherapy or with MTX | FDA Approved |
| Ankylosing spondylitis | Adults | Monotherapy | FDA Approved |
| Plaque psoriasis (chronic, moderate-to-severe) | Adults ≥18 years; pediatric ≥4 years | Candidates for systemic or phototherapy | FDA Approved |
Etanercept was the first soluble TNF receptor approved for RA (1998). In the ACR 2021 guidelines, TNF inhibitors including etanercept are conditionally recommended over non-TNF biologics for patients with moderate-to-high disease activity despite csDMARD therapy. Unlike anti-TNF monoclonal antibodies, etanercept binds both TNF-alpha and lymphotoxin (TNF-beta). Etanercept is not effective in granulomatous diseases (Crohn disease, sarcoidosis) — a key clinical distinction from infliximab and adalimumab. The TEMPO trial demonstrated that etanercept plus methotrexate was superior to either agent alone in slowing radiographic progression in RA.
Dosing for Etanercept
Adult Dosing
| Indication | Dose | Frequency | Maximum | Notes |
|---|---|---|---|---|
| RA, PsA, AS | 50 mg SC | Once weekly | 50 mg/week | Alternative: 25 mg SC twice weekly (72–96 h apart) May be used with MTX, glucocorticoids, NSAIDs, or analgesics; doses >50 mg/week not recommended |
| Plaque psoriasis (adults) | 50 mg SC twice weekly | BIW × 3 months (induction), then 50 mg QW | 100 mg/week (induction only) | Starting doses of 25 mg or 50 mg QW also shown efficacious Response is dose-related; higher induction dose for faster onset |
Pediatric Dosing
| Indication | Dose | Frequency | Maximum | Notes |
|---|---|---|---|---|
| pJIA (≥2 years) | 0.8 mg/kg SC | Once weekly | 50 mg/week | Patients ≥63 kg may use fixed 50 mg dose Alternative: 0.4 mg/kg SC twice weekly (max 50 mg/week) |
| Pediatric PsO (≥4 years) | 0.8 mg/kg SC | Once weekly | 50 mg/week | Patients ≥63 kg may use fixed 50 mg dose |
Before initiating etanercept, complete: (1) TB screening (TST or IGRA) — treat latent TB before starting; (2) Hepatitis B serology (HBsAg, anti-HBc, anti-HBs); (3) Hepatitis C screening; (4) CBC with differential; (5) Assess for active infections; (6) Evaluate heart failure status — avoid in NYHA class III/IV; (7) Review vaccination status — administer all age-appropriate vaccinations (especially pneumococcal, influenza) before starting; avoid live vaccines during therapy; (8) Evaluate demyelinating disease history.
Pharmacology of Etanercept
Mechanism of Action
Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1. It acts as a decoy receptor, competitively binding circulating TNF-alpha and lymphotoxin (TNF-beta) and preventing them from engaging cell-surface TNF receptors. This blocks TNF-mediated inflammatory signalling, reducing synovial inflammation, pannus formation, and joint destruction. Unlike monoclonal anti-TNF antibodies (infliximab, adalimumab), etanercept binds both TNF-alpha and lymphotoxin, does not fix complement, and does not lyse TNF-expressing cells. This mechanistic difference may explain its lower risk of tuberculosis reactivation compared to monoclonal antibodies, as well as its lack of efficacy in granulomatous diseases such as Crohn disease.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Slowly absorbed from SC injection site; Tmax 48–60 h; absolute bioavailability ~58% | Steady state reached in 2–4 weeks; 50 mg QW and 25 mg BIW produce comparable systemic exposure |
| Distribution | Vd apparent ~12 L; distributes into synovial fluid; 934 amino acids, ~150 kDa | Large molecular weight limits distribution primarily to vascular and interstitial spaces; penetrates into inflamed joints |
| Metabolism | Catabolised by proteolytic degradation via the reticuloendothelial system (liver, spleen); not metabolised by CYP enzymes | No CYP-mediated drug interactions; PK unaffected by concurrent MTX, warfarin, or digoxin |
| Elimination | t½ ~70 h (range 70–100 h); CL/F 0.089–0.137 L/h; no renal or hepatic dose adjustment needed | Shorter half-life than adalimumab (~14 days) or infliximab (~10 days); faster washout if adverse events occur; PK unaffected by age, gender, ethnicity, or renal impairment |
Side Effects of Etanercept
The following incidence data are from placebo-controlled clinical trials in RA, PsA, AS, and PsO as reported in the FDA-approved prescribing information. Across clinical studies and postmarketing experience, the most serious adverse reactions were infections, neurologic events, CHF, and haematologic events.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reactions (erythema, pain, swelling, pruritus) | 37% (RA); 15% (PsO adults); 36% (JIA) | Usually within first month; duration 3–5 days; mild-moderate; generally do not necessitate discontinuation; recall reactions at previous sites in ~7% |
| Upper respiratory tract infections | ~20% (RA); ~12% (PsO) | Rates similar to placebo in controlled trials; includes sinusitis, pharyngitis, rhinitis |
| Headache | ~17% (RA) | Usually self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | ~9% | Usually self-limiting |
| Rash (non-injection-site) | ~5% | Distinguish from new/worsening psoriasis |
| Diarrhoea | ~8% | Usually self-limiting |
| Dizziness | ~7% | Usually self-limiting |
| Abdominal pain | ~5% | Evaluate for GI infection if persistent |
| Pruritus | ~5% | May occur at non-injection sites |
| New positive ANA | 11% (vs 5% placebo) | Usually not clinically significant; anti-dsDNA: 15% by RIA vs 4% placebo |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (pneumonia, cellulitis, septic arthritis, sepsis, abscess) ⚠️ BOXED | ~1% (similar to placebo in trials); higher in real-world use | Any time; some within weeks of starting | Do not start during active infection; interrupt if serious infection develops; evaluate and treat before resuming |
| Tuberculosis (active or reactivation) ⚠️ BOXED | ~0.006% (in 17,696 patients) | Any time; lower risk than with anti-TNF monoclonal antibodies | Screen before starting and periodically; treat latent TB before initiating; monitor for signs of active TB |
| Invasive fungal infections (Histoplasma, Aspergillus, Candida, Pneumocystis) ⚠️ BOXED | Very rare (0.09% opportunistic infections overall) | Any time | Consider empiric antifungal therapy in endemic areas; discontinue etanercept and treat aggressively |
| Malignancies (lymphoma, NMSC, melanoma) ⚠️ BOXED | Lymphoma: increased vs general population but RA itself confers risk; NMSC: increased vs controls | Variable; hepatosplenic T-cell lymphoma (HSTCL) reported in adolescents/young adults on combination TNFi + thiopurines | Periodic skin examinations; counsel on malignancy risk; caution in patients with prior malignancy |
| Demyelinating disorders (MS, optic neuritis, transverse myelitis) | Rare | Any time; new onset or exacerbation | Avoid in patients with pre-existing demyelinating disease; discontinue if symptoms develop; neurologic evaluation |
| Heart failure (worsening or new-onset) | Uncommon | Any time; RENAISSANCE/RECOVER trials showed no benefit in CHF | Avoid in NYHA class III/IV; use with caution in class I/II; discontinue if CHF worsens |
| Hepatitis B reactivation | Rare | Any time; can occur in HBsAg-negative/anti-HBc-positive patients | Screen before starting; monitor HBV carriers; consult hepatologist if reactivation occurs; stop etanercept |
| Pancytopenia / aplastic anaemia | Rare | Any time | Monitor CBC; discontinue if significant cytopenia confirmed |
| Lupus-like syndrome / autoimmune hepatitis | Rare | Variable | Stop etanercept if lupus-like syndrome or autoimmune hepatitis develops |
| New or worsening psoriasis (paradoxical) | Uncommon | Variable; including pustular and palmoplantar forms | Evaluate; may resolve on its own; consider discontinuation if severe |
Serious infections: Patients treated with etanercept are at increased risk for developing serious infections that may lead to hospitalisation or death. Most patients who developed these infections were on concomitant immunosuppressants. Discontinue etanercept if a patient develops a serious infection. Reported infections include active tuberculosis (including reactivation of latent TB), invasive fungal infections, and bacterial, viral, and other opportunistic infections. Evaluate for TB risk factors and test for latent TB before starting. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
Malignancies: Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare and often fatal lymphoma, have been reported in adolescents and young adults using TNF blockers in combination with azathioprine or 6-mercaptopurine for inflammatory bowel disease.
Drug Interactions with Etanercept
Etanercept has a relatively favourable drug interaction profile since it is not metabolised by CYP enzymes. Its PK is unaffected by concurrent MTX, warfarin, or digoxin. The key interactions are pharmacodynamic — related to additive immunosuppression or immune modulation.
Monitoring for Etanercept
- TB screening (TST or IGRA)Baseline mandatory; periodically during therapy
RoutineTreat latent TB before initiating etanercept; TB has developed in patients who tested negative at baseline; consider repeat testing annually or in high-risk patients - Hepatitis B serologyBaseline mandatory
RoutineCheck HBsAg, anti-HBc, anti-HBs; monitor HBV carriers throughout therapy and for several months after stopping; consult hepatologist if reactivation occurs - CBC with differentialBaseline, then periodically
RoutineScreen for pancytopenia, neutropenia, aplastic anaemia; advise patients to seek medical attention for signs of blood dyscrasias (persistent fever, bruising, pallor) - Signs of infectionEvery visit
RoutineEvaluate for fever, cough, dyspnoea, wound infections; interrupt etanercept if serious infection develops; do not initiate in patients with active infection - Heart failure assessmentBaseline; ongoing if history of CHF
Trigger-basedAvoid in NYHA III/IV; monitor for dyspnoea, oedema, weight gain in at-risk patients; discontinue if CHF worsens - Neurologic symptomsIf new symptoms
Trigger-basedNew numbness, visual changes, weakness may suggest demyelination; discontinue and refer for neurologic evaluation - Skin cancer screeningPeriodic, especially in patients with risk factors
RoutineHigher NMSC rates observed; periodic dermatologic examination recommended for all patients, particularly those with prior skin cancer or extensive immunosuppression
Contraindications & Cautions for Etanercept
Absolute Contraindications
- Sepsis — risk of fatal outcome
- Active serious infection — including active TB, active hepatitis B, invasive fungal infections, active herpes zoster
- Hypersensitivity to etanercept or any component
Relative Contraindications (Specialist Input Recommended)
- Heart failure (NYHA class III/IV) — may worsen CHF; avoid use
- Demyelinating disorders — pre-existing MS, optic neuritis, or transverse myelitis
- Untreated latent TB — must treat before initiating etanercept
- Chronic hepatitis B carriers — risk of reactivation; monitor closely if treatment essential
- Moderate-to-severe heart failure (NYHA class I/II) — use with caution; monitor closely
Use with Caution
- History of recurrent infections — increased susceptibility
- History of or current malignancy — weigh benefit vs risk; NMSC risk is increased
- Concurrent immunosuppressive therapy — avoid combining with other biologics or JAK inhibitors
- Elderly patients — higher incidence of infections in general; enhanced vigilance
- Pregnancy and lactation — no reliable association with birth defects but use only if clearly needed
Patient Counselling for Etanercept
Purpose of Therapy
Explain that etanercept works by blocking TNF, a chemical messenger that drives inflammation and joint damage in rheumatoid arthritis and related conditions. Unlike traditional DMARDs, it targets a specific part of the immune system. It is given as a weekly injection under the skin and can be self-administered at home after proper training. Improvement may begin within 1–2 weeks, but full benefit develops over 3–6 months.
Sources
- Enbrel (etanercept) — Full Prescribing Information. Immunex Corporation (Amgen). Revised September 2024. FDA Label PDF Primary source for approved indications, dosing, boxed warnings, adverse reactions with incidence rates, drug interactions, PK data, and monitoring recommendations.
- Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999;130(6):478-486. DOI Pivotal RA Study I demonstrating significant ACR 20/50 responses with etanercept 25 mg BIW vs placebo.
- Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259. DOI RA Study III demonstrating efficacy and safety of adding etanercept to background MTX therapy.
- Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-1593. DOI ERA trial — etanercept was more effective than MTX in slowing radiographic progression in early RA over 12 months.
- Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis (TEMPO trial). Lancet. 2004;363(9410):675-681. DOI TEMPO trial — etanercept + MTX superior to either alone for clinical, functional, and radiographic outcomes in RA.
- Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014-2022. DOI Pivotal plaque psoriasis study establishing efficacy of etanercept 25 mg BIW and 50 mg BIW in moderate-to-severe PsO.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924-939. DOI Current ACR guideline conditionally recommending TNF inhibitors (including etanercept) for RA with inadequate csDMARD response.
- Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. DOI EULAR RA management recommendations including bDMARDs after csDMARD failure.
- Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490-497. DOI Comprehensive PK review: bioavailability 58%, t½ 70–100 h, no dose adjustment for MTX/warfarin/digoxin, renal/hepatic impairment.
- Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258-265. DOI Systematic review and meta-analysis quantifying serious infection risk with biologic DMARDs in RA, including etanercept.
- Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285. DOI Meta-analysis quantifying infection and malignancy risks with anti-TNF therapies in RA.